ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that a.macht contributed 24 entries already.
As artificial intelligence reshapes life sciences research, two leading Elsevier Gold Open Access peer-reviewed journals, SLAS Discovery and SLAS Technology, invite contributions to Special Issues exploring how AI, automation and self-driving laboratories are transforming drug discovery. Submissions are accepted until 15 December 2026.
The appointment of Ponchi marking an important milestone in the company’s global commercial strategy and further strengthening its commercial leadership as the company continues to expand its presence in the global CDMO market.
With the separation from the biobank service business, Hamburg-based Indivumed has repositioned itself as a therapeutics biotech. Its earlier work remains the core of its medical knowledge and the source of novel targets. To advance the already pre-validated selection more quickly, the company is now looking for partners. The response has been strong, say Matthias Evers and Hartmut Juhl in conversation with European Biotechnology Magazine.
3PBIOVIAN has added an additional 2,000-liter single-use bioreactor for mammalian cell culture, further strengthening its industrial capacity and reinforcing its value proposition as a CDMO partner for the development and manufacturing of recombinant proteins.
The AI Circular Economy Conference 2026, organised by nova-Institute, brought together 116 participants from 15 countries in Cologne and online to explore the transformation of the chemical and materials industry supported and accelerated by artificial intelligence.
The “16th European Biotechnology Science & Industry Guide 2026” presents the strengths and core competencies of companies and institutions in the fields of Biotech, Biopharma, BioServices and BioManufacturing in Europe.
3PBIOVIAN consolidates its position as a trusted partner for the development and manufacturing of complex biological products, combining scientific excellence, regulatory expertise, and strong social commitment.
Organoids are reshaping cancer R&D by providing more accurate, patient-relevant models than classical methods. By bridging the gap between preclinical and early clinical stages, they enable patient-centric target validation, drug discovery, and therapeutic development, representing a significant step toward truly precision oncology
Watch this expert-led session to explore the latest trends and insights in gene therapy, including how to model immunosuppressive regimens, key study-design considerations, and the importance of age categories in nonhuman primate research.
Download the guide to explore how forward-thinking organisations are leveraging digital transformation in manufacturing to overcome regulatory challenges, enhance compliance, and gain operational efficiencies across multiple European sites and jurisdictions.